FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975779124> ?p ?o ?g. }

• W2975779124 endingPage "1768" @default.
• W2975779124 startingPage "1760" @default.
• W2975779124 abstract "Dabigatran and idarucizumab, its reversal agent, are renally cleared.The purpose of this study was to determine the extent of reversal and outcomes according to baseline renal function in dabigatran-treated nondialysis patients receiving idarucizumab.In 503 patients in RE-VERSE AD (Reversal of Effects of Idarucizumab in Patients on Active Dabigatran), the extent of dabigatran reversal and clinical outcomes were compared according to baseline renal function (creatinine clearance: normal ≥80, mild 50 to <80, moderate 30 to <50, and severe <30 ml/min).Compared with patients with normal renal function, those with impaired renal function were older, were more often women, and had lower body mass indexes, more comorbidities, higher CHADS2 scores, and higher dabigatran plasma levels despite more frequent use of lower-dose dabigatran regimens. Regardless of renal function, median reversal measured by dilute thrombin time was 100% within 4 h of idarucizumab administration, and over 98% of patients achieved this with corresponding undetectable levels of unbound dabigatran. By 12 or 24 h, 56% of patients with severe, 29.1% with moderate, and 9.2% with mild renal impairment had dabigatran levels >20 ng/ml compared with 8.3% of patients with normal renal function at baseline. Time to cessation of bleeding and the proportion with normal hemostasis with procedures were similar regardless of renal function, but patients with severe renal impairment had higher 30- and 90-day mortality rates.Idarucizumab completely reverses dabigatran in >98% of patients regardless of renal function. Although re-elevation of dabigatran levels within 12 to 24 h is more common with renal impairment, the time to bleeding cessation and the extent of hemostasis during procedures are similar. (Reversal of Dabigatran Anticoagulant Effect With Idarucizumab; NCT02104947)." @default.
• W2975779124 created "2019-10-03" @default.
• W2975779124 creator A5037293929 @default.
• W2975779124 creator A5041656388 @default.
• W2975779124 creator A5048154042 @default.
• W2975779124 creator A5077997134 @default.
• W2975779124 creator A5080799947 @default.
• W2975779124 creator A5081398468 @default.
• W2975779124 creator A5082464840 @default.
• W2975779124 creator A5087630518 @default.
• W2975779124 date "2019-10-01" @default.
• W2975779124 modified "2023-09-29" @default.
• W2975779124 title "Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment" @default.
• W2975779124 cites W1547546593 @default.
• W2975779124 cites W1641613989 @default.
• W2975779124 cites W1971941179 @default.
• W2975779124 cites W1981340953 @default.
• W2975779124 cites W2015751459 @default.
• W2975779124 cites W2034607173 @default.
• W2975779124 cites W2062946016 @default.
• W2975779124 cites W2106760090 @default.
• W2975779124 cites W2126850212 @default.
• W2975779124 cites W2130909191 @default.
• W2975779124 cites W2136489990 @default.
• W2975779124 cites W2142187440 @default.
• W2975779124 cites W2431219546 @default.
• W2975779124 cites W2514338974 @default.
• W2975779124 cites W2734827407 @default.
• W2975779124 cites W2784115121 @default.
• W2975779124 cites W2794034196 @default.
• W2975779124 cites W2914381505 @default.
• W2975779124 doi "https://doi.org/10.1016/j.jacc.2019.07.070" @default.
• W2975779124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31582135" @default.
• W2975779124 hasPublicationYear "2019" @default.
• W2975779124 type Work @default.
• W2975779124 sameAs 2975779124 @default.
• W2975779124 citedByCount "18" @default.
• W2975779124 countsByYear W29757791242019 @default.
• W2975779124 countsByYear W29757791242020 @default.
• W2975779124 countsByYear W29757791242021 @default.
• W2975779124 countsByYear W29757791242022 @default.
• W2975779124 countsByYear W29757791242023 @default.
• W2975779124 crossrefType "journal-article" @default.
• W2975779124 hasAuthorship W2975779124A5037293929 @default.
• W2975779124 hasAuthorship W2975779124A5041656388 @default.
• W2975779124 hasAuthorship W2975779124A5048154042 @default.
• W2975779124 hasAuthorship W2975779124A5077997134 @default.
• W2975779124 hasAuthorship W2975779124A5080799947 @default.
• W2975779124 hasAuthorship W2975779124A5081398468 @default.
• W2975779124 hasAuthorship W2975779124A5082464840 @default.
• W2975779124 hasAuthorship W2975779124A5087630518 @default.
• W2975779124 hasBestOaLocation W29757791241 @default.
• W2975779124 hasConcept C126322002 @default.
• W2975779124 hasConcept C126894567 @default.
• W2975779124 hasConcept C159641895 @default.
• W2975779124 hasConcept C2776301958 @default.
• W2975779124 hasConcept C2776413415 @default.
• W2975779124 hasConcept C2778810321 @default.
• W2975779124 hasConcept C2779161974 @default.
• W2975779124 hasConcept C2908822073 @default.
• W2975779124 hasConcept C42219234 @default.
• W2975779124 hasConcept C71924100 @default.
• W2975779124 hasConceptScore W2975779124C126322002 @default.
• W2975779124 hasConceptScore W2975779124C126894567 @default.
• W2975779124 hasConceptScore W2975779124C159641895 @default.
• W2975779124 hasConceptScore W2975779124C2776301958 @default.
• W2975779124 hasConceptScore W2975779124C2776413415 @default.
• W2975779124 hasConceptScore W2975779124C2778810321 @default.
• W2975779124 hasConceptScore W2975779124C2779161974 @default.
• W2975779124 hasConceptScore W2975779124C2908822073 @default.
• W2975779124 hasConceptScore W2975779124C42219234 @default.
• W2975779124 hasConceptScore W2975779124C71924100 @default.
• W2975779124 hasFunder F4320307115 @default.
• W2975779124 hasFunder F4320307765 @default.
• W2975779124 hasFunder F4320307770 @default.
• W2975779124 hasFunder F4320307771 @default.
• W2975779124 hasFunder F4320307779 @default.
• W2975779124 hasFunder F4320307813 @default.
• W2975779124 hasFunder F4320310420 @default.
• W2975779124 hasFunder F4320310441 @default.
• W2975779124 hasFunder F4320312415 @default.
• W2975779124 hasFunder F4320321625 @default.
• W2975779124 hasFunder F4320337601 @default.
• W2975779124 hasIssue "14" @default.
• W2975779124 hasLocation W29757791241 @default.
• W2975779124 hasLocation W29757791242 @default.
• W2975779124 hasOpenAccess W2975779124 @default.
• W2975779124 hasPrimaryLocation W29757791241 @default.
• W2975779124 hasRelatedWork W1993426051 @default.
• W2975779124 hasRelatedWork W2022616407 @default.
• W2975779124 hasRelatedWork W2276716999 @default.
• W2975779124 hasRelatedWork W2362524069 @default.
• W2975779124 hasRelatedWork W2464106697 @default.
• W2975779124 hasRelatedWork W2535953127 @default.
• W2975779124 hasRelatedWork W2560325528 @default.
• W2975779124 hasRelatedWork W2789346949 @default.
• W2975779124 hasRelatedWork W2975779124 @default.
• W2975779124 hasRelatedWork W2525393404 @default.

• next